159 related articles for article (PubMed ID: 32820148)
1. Hippo/MST blocks breast cancer by downregulating WBP2 oncogene expression via miRNA processor Dicer.
Lim SK; Tabatabaeian H; Lu SY; Kang SA; Sundaram GM; Sampath P; Chan SW; Hong WJ; Lim YP
Cell Death Dis; 2020 Aug; 11(8):669. PubMed ID: 32820148
[TBL] [Abstract][Full Text] [Related]
2. WBP2 inhibits microRNA biogenesis via interaction with the microprocessor complex.
Tabatabaeian H; Lim SK; Chu T; Seah SH; Lim YP
Life Sci Alliance; 2021 Jul; 4(7):. PubMed ID: 34117091
[TBL] [Abstract][Full Text] [Related]
3. Wnt Signaling Promotes Breast Cancer by Blocking ITCH-Mediated Degradation of YAP/TAZ Transcriptional Coactivator WBP2.
Lim SK; Lu SY; Kang SA; Tan HJ; Li Z; Adrian Wee ZN; Guan JS; Reddy Chichili VP; Sivaraman J; Putti T; Thike AA; Tan PH; Sudol M; Virshup DM; Chan SW; Hong W; Lim YP
Cancer Res; 2016 Nov; 76(21):6278-6289. PubMed ID: 27578003
[TBL] [Abstract][Full Text] [Related]
4. The transcriptional coactivator WBP2 primes triple-negative breast cancer cells for responses to Wnt signaling via the JNK/Jun kinase pathway.
Li Z; Lim SK; Liang X; Lim YP
J Biol Chem; 2018 Dec; 293(52):20014-20028. PubMed ID: 30442712
[TBL] [Abstract][Full Text] [Related]
5. The Hippo pathway effectors TAZ/YAP regulate dicer expression and microRNA biogenesis through Let-7.
Chaulk SG; Lattanzi VJ; Hiemer SE; Fahlman RP; Varelas X
J Biol Chem; 2014 Jan; 289(4):1886-91. PubMed ID: 24324261
[TBL] [Abstract][Full Text] [Related]
6. WBP2 promotes gastric cancer cell migration via novel targeting of LATS2 kinase in the Hippo tumor suppressor pathway.
Hum M; Tan HJ; Yang Y; Srivastava S; Teh M; Lim YP
FASEB J; 2021 Feb; 35(2):e21290. PubMed ID: 33475198
[TBL] [Abstract][Full Text] [Related]
7. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
[TBL] [Abstract][Full Text] [Related]
8. The emerging roles of WBP2 oncogene in human cancers.
Tabatabaeian H; Rao A; Ramos A; Chu T; Sudol M; Lim YP
Oncogene; 2020 Jun; 39(24):4621-4635. PubMed ID: 32393834
[TBL] [Abstract][Full Text] [Related]
9. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility.
Wang Z; Wu Y; Wang H; Zhang Y; Mei L; Fang X; Zhang X; Zhang F; Chen H; Liu Y; Jiang Y; Sun S; Zheng Y; Li N; Huang L
Proc Natl Acad Sci U S A; 2014 Jan; 111(1):E89-98. PubMed ID: 24367099
[TBL] [Abstract][Full Text] [Related]
10. WBP2 modulates G1/S transition in ER+ breast cancer cells and is a direct target of miR-206.
Ren YQ; Wang HJ; Zhang YQ; Liu YB
Cancer Chemother Pharmacol; 2017 May; 79(5):1003-1011. PubMed ID: 28391353
[TBL] [Abstract][Full Text] [Related]
11. WBP2 negatively regulates the Hippo pathway by competitively binding to WWC3 with LATS1 to promote non-small cell lung cancer progression.
Han Q; Rong X; Lin X; Zhang X; Fan C; Zhao H; Wang E
Cell Death Dis; 2021 Apr; 12(4):384. PubMed ID: 33837178
[TBL] [Abstract][Full Text] [Related]
12. MARK4 inhibits Hippo signaling to promote proliferation and migration of breast cancer cells.
Heidary Arash E; Shiban A; Song S; Attisano L
EMBO Rep; 2017 Mar; 18(3):420-436. PubMed ID: 28183853
[TBL] [Abstract][Full Text] [Related]
13. WW domain-binding protein 2: an adaptor protein closely linked to the development of breast cancer.
Chen S; Wang H; Huang YF; Li ML; Cheng JH; Hu P; Lu CH; Zhang Y; Liu N; Tzeng CM; Zhang ZM
Mol Cancer; 2017 Jul; 16(1):128. PubMed ID: 28724435
[TBL] [Abstract][Full Text] [Related]
14. YAP-Hippo signalling downstream of leukemia inhibitory factor receptor: implications for breast cancer.
Hergovich A
Breast Cancer Res; 2012 Dec; 14(6):326. PubMed ID: 23216692
[TBL] [Abstract][Full Text] [Related]
15. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
Hao Y; Chun A; Cheung K; Rashidi B; Yang X
J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
[TBL] [Abstract][Full Text] [Related]
16. MDA-7/IL-24 regulates the miRNA processing enzyme DICER through downregulation of MITF.
Pradhan AK; Bhoopathi P; Talukdar S; Scheunemann D; Sarkar D; Cavenee WK; Das SK; Emdad L; Fisher PB
Proc Natl Acad Sci U S A; 2019 Mar; 116(12):5687-5692. PubMed ID: 30842276
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent differential mRNA target selection and regulation by let-7a-7f and miR-17-92 cluster microRNAs.
Shu J; Xia Z; Li L; Liang ET; Slipek N; Shen D; Foo J; Subramanian S; Steer CJ
RNA Biol; 2012 Oct; 9(10):1275-87. PubMed ID: 22995834
[TBL] [Abstract][Full Text] [Related]
18. Reciprocal Regulation of Hippo and WBP2 Signalling-Implications in Cancer Therapy.
Lim YX; Lin H; Seah SH; Lim YP
Cells; 2021 Nov; 10(11):. PubMed ID: 34831354
[TBL] [Abstract][Full Text] [Related]
19. WW domain-mediated interaction with Wbp2 is important for the oncogenic property of TAZ.
Chan SW; Lim CJ; Huang C; Chong YF; Gunaratne HJ; Hogue KA; Blackstock WP; Harvey KF; Hong W
Oncogene; 2011 Feb; 30(5):600-10. PubMed ID: 20972459
[TBL] [Abstract][Full Text] [Related]
20. MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer.
Cochrane DR; Cittelly DM; Howe EN; Spoelstra NS; McKinsey EL; LaPara K; Elias A; Yee D; Richer JK
Horm Cancer; 2010 Dec; 1(6):306-19. PubMed ID: 21761362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
